Literature DB >> 12834856

A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding.

Ellen Z Baum1, Pamela C Wagaman, Linh Ly, Ignatius Turchi, Jianhua Le, Doris Bucher, Karen Bush.   

Abstract

The influenza neuraminidase (NA) inhibitors peramivir, oseltamivir, and zanamivir are potent inhibitors of NAs from both influenza A and B strains. In general, these inhibitors are slow, tight binders of NA, exhibiting time-dependent inhibition. A mutant of influenza virus B/Yamagata/16/88 which was resistant to peramivir was generated by passage of the virus in tissue culture, in the presence of increasing concentrations (0.1-120 microM over 15 passages) of the compound. Whereas the wild type (WT) virus was inhibited by peramivir with an EC(50) value of 0.10 microM, virus isolated at passages 3 and 15 displayed EC(50) values of 10 and >50 microM, respectively. Passage 3 virus contained 3 hemagglutinin (HA) mutations, but no NA mutation. Passage 15 (P15R) virus contained an additional 3 HA mutations, plus the NA mutation His273Tyr. The mechanism of inhibition of WT and P15R NA by peramivir was examined in enzyme assays. The WT and P15R NAs displayed IC(50) values of 8.4+/-0.4 and 127+/-16 nM, respectively, for peramivir. Peramivir inhibited the WT enzyme in a time-dependent fashion, with a K(i) value of 0.066+/-0.002nM. In contrast, the P15R enzyme did not display the property of slow binding and was inhibited competitively with a K(i) value of 4.69+/-0.44nM. Molecular modeling suggested that His273 was relatively distant from peramivir (>5A) in the NA active site, but that Tyr273 introduced a repulsive interaction between the enzyme and inhibitor, which may have been responsible for peramivir resistance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12834856     DOI: 10.1016/s0166-3542(03)00011-1

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  21 in total

1.  Recovery of influenza B virus with the H273Y point mutation in the neuraminidase active site from a human patient.

Authors:  Rachel R Higgins; Melissa Beniprashad; Eddie Chong-King; Yan Li; Nathalie Bastien; Donald E Low; Jonathan B Gubbay
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

2.  Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181.

Authors:  Gallen B Triana-Baltzer; Rebecca L Sanders; Maria Hedlund; Kellie A Jensen; Laura M Aschenbrenner; Jeffrey L Larson; Fang Fang
Journal:  J Antimicrob Chemother       Date:  2010-11-21       Impact factor: 5.790

Review 3.  Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance.

Authors:  Andrew J Burnham; Tatiana Baranovich; Elena A Govorkova
Journal:  Antiviral Res       Date:  2013-09-04       Impact factor: 5.970

4.  Solid phase assay for comparing reactivation rates of neuraminidases of influenza wild type and resistant mutants after inhibitor removal.

Authors:  Susan Barrett; Jennifer L McKimm-Breschkin
Journal:  Antiviral Res       Date:  2014-05-20       Impact factor: 5.970

5.  Fitness costs for Influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y.

Authors:  Andrew J Burnham; Tatiana Baranovich; Bindumadhav M Marathe; Jianling Armstrong; Robert G Webster; Elena A Govorkova
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

6.  Influenza virus resistance to neuraminidase inhibitors: implications for treatment.

Authors:  Shivanjali Shankaran; Gonzalo M L Bearman
Journal:  Curr Infect Dis Rep       Date:  2012-04       Impact factor: 3.725

7.  Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.

Authors:  Aaron J Oakley; Susan Barrett; Thomas S Peat; Janet Newman; Victor A Streltsov; Lynne Waddington; Takehiko Saito; Masato Tashiro; Jennifer L McKimm-Breschkin
Journal:  J Med Chem       Date:  2010-09-09       Impact factor: 7.446

8.  Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.

Authors:  Tiffany G Sheu; Varough M Deyde; Margaret Okomo-Adhiambo; Rebecca J Garten; Xiyan Xu; Rick A Bright; Eboneé N Butler; Teresa R Wallis; Alexander I Klimov; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

9.  Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice.

Authors:  David A Boltz; Natalia A Ilyushina; C Shane Arnold; Y Sudhakar Babu; Robert G Webster; Elena A Govorkova
Journal:  Antiviral Res       Date:  2008-06-23       Impact factor: 5.970

10.  Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein.

Authors:  Gallen B Triana-Baltzer; Larisa V Gubareva; Alexander I Klimov; David F Wurtman; Ronald B Moss; Maria Hedlund; Jeffrey L Larson; Robert B Belshe; Fang Fang
Journal:  PLoS One       Date:  2009-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.